We extended these studies on the potential induction of Foxp3 expression in CD4+ non-Treg by examining a cohort of patients who were developing acute GVHD or who manifested signs of chronic GVHD following HCT for malignancies (Tables 1A–C). The gene discussed is FOXP3; the disease is chronic graft versus host disease.